Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.
10.1007/s13238-016-0327-9
- Author:
Xuelin ZHANG
1
;
Yang WANG
2
;
Pingsheng LIU
3
Author Information
1. School of Kinesiology and Health, Capital University of Physical Education and Sports, Beijing, 100191, China. zhangxuelin@cupes.edu.cn.
2. National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
3. National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. pliu@ibp.ac.cn.
- Publication Type:Journal Article
- Keywords:
17β-HSD13;
PNPLA3;
genome-wide association study;
lipid droplets;
non-alcoholic fatty liver disease;
proteomics
- MeSH:
17-Hydroxysteroid Dehydrogenases;
genetics;
metabolism;
Animals;
Genome-Wide Association Study;
Genomics;
Humans;
Lipid Droplets;
metabolism;
Lipid Metabolism;
genetics;
Non-alcoholic Fatty Liver Disease;
genetics;
metabolism;
Proteomics
- From:
Protein & Cell
2017;8(1):4-13
- CountryChina
- Language:English
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is an epidemic metabolic condition driven by an underlying lipid homeostasis disorder. The lipid droplet (LD), the main organelle involved in neutral lipid storage and hydrolysis, is a potential target for NAFLD therapeutic treatment. In this review, we summarize recent progress elucidating the connections between LD-associated proteins and NAFLD found by genome-wide association studies (GWAS), genomic and proteomic studies. Finally, we discuss a possible mechanism by which the protein 17β-hydroxysteroid dehydrogenase 13 (17β-HSD13) may promote the development of NAFLD.
